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Hepatocellular carcinoma presenting as rib lesion: A diagnostic dilemma
Editor, Hepatocellular carcinoma (HCC) is the most frequent primary malignant tumor of the liver, the fifth most common malignancy worldwide, the third leading cause of cancer-related deaths, and is endemic in developing countries and Southeast Asia. HCC commonly metastasizes to regional lymph nodes and lungs and primary presentation with skeletal metastases is rare. [1] [2] [3] A 60-year-old female patient presented with complaints of swelling on chest wall, cough, and fatigue since 1 month. Physical examination showed a palpable swelling overlying the right eight rib. Ultrasound examination revealed hepatomegaly and retroperitoneal lymphadenopathy, which was confirmed by contrast enhanced computed tomography (CECT), scan. CECT scan also showed an expansile lytic lesion in right eight rib with soft tissue mass and extrapleural extension in chest. A tiny cyst was seen in right lobe of liver.
TruCut biopsy of rib lesion was done for diagnosis, and the histopathology showed sheets of polygonal cells with clear or foamy cytoplasm and small to medium sized nuclei with variably prominent nucleoli. There was no obvious trabecular or pseudoglandular architecture. Mitoses were rare, and no hemorrhage or necrosis was evident. Immunohistochemistry showed strong positivity of tumor cells for HepPar1 and were negative for EMA, CK7, and CK20[ Figure 1 ]. A diagnosis of moderately differentiated clear cell HCC was made.
18F-FDG PET (positron emission tomography) scan detected an FDG (fluoro-2-deoxy-d-glucose) avid ill-defined hypodense lesion in liver, along with a hepatic cyst, and metabolically active mass lesions in breast and vertebra. Biochemical tests also showed elevated AFP (93.2 ng/mL) and CA-125 (54 U/ml) levels. CEA levels, routine biochemical parameters, and viral markers were normal. The patient received palliative radiotherapy and care. Patient was lost to follow-up after 1 year.
Metastasis of HCC occurs frequently by way of intrahepatic blood vessels, lymphatic permeation, or direct infiltration. Low survival rates for patients with HCC have resulted in low incidences of symptomatic extrahepatic metastases, such as lung and bone metastases (0%-5%). Few reports suggest that though uncommon, HCC should be considered in the differential diagnosis of patients presenting with bone metastases, and these can very rarely be the primary manifestation. Metastatic spread of HCC to the bones occurs in 13%-16% cases. [1, 3] Other metastatic tumors, notably from the breast, kidney, and adrenal glands, may mimic HCC; and immunohistochemistry (IHC) is useful, especially in those cases with initial presentation of HCC as a metastasis. Morphological differentiation of clear cell HCC from clear cell renal carcinoma, which was a problem in the reported case, may not be possible without the aid of IHC. HepPar-1 (anti-hepatocyte-specific antigen) is highly sensitive for normal and neoplastic hepatocytes. A positive HepPar-1 (clone OCH1E5) by IHC is sufficient for a diagnosis of HCC-CC, if enough tissue is available. [4] CA-125 and α-fetoprotein tumor markers are sensitive and specific, respectively, for HCC and are used for diagnosis and therapy monitoring. As a screening tool of extrahepatic metastasis of HCC, PET CT scan is invaluable for detection of lung metastases larger than 1 cm and bone metastases. [5] The extent of intrahepatic lesions and liver performance status are important prognostic determinants in the majority of patients with HCC, rather than the presence of extrahepatic metastases. However, poor prognosis of patients with extrahepatic metastasis in HCC might not improve despite aggressive treatment. [6, 7] This report underlines the importance of identifying typical histomorphological features of this rare metastatic lesion even in the absence of overt hepatic lesions or symptoms.
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